Two Sigma Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Two Sigma Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,600	Closed	-$237K	–	1499
2024 Q4	$237K	Sell	3,600 -5,500	-60%	-$368K	0.03%	829
2024 Q3	$640K	Sell	9,100 -1,400	-13%	-$117K	0.01%	1135
2024 Q2	$864K	Buy	+10,500	New	+$874K	0.01%	1164
2021 Q1	–	Sell	-8,800	Closed	-$772K	–	917
2020 Q4	$772K	Buy	+8,800	New	+$698K	0.02%	491
2020 Q3	–	Sell	-13,800	Closed	-$1.7M	–	1306
2020 Q2	$1.7M	Buy	13,800 +8,300	+151%	+$825K	0.04%	265
2020 Q1	$465K	Sell	5,500 -3,000	-35%	-$258K	0.01%	650
2019 Q4	$719K	Buy	8,500 +1,700	+25%	+$128K	﹤0.01%	1232
2019 Q3	$458K	Buy	6,800 +900	+15%	+$69.3K	﹤0.01%	1263
2019 Q2	$505K	Buy	5,900 +2,900	+97%	+$248K	0.01%	1111
2019 Q1	$266K	Buy	+3,000	New	+$278K	﹤0.01%	1272
2018 Q4	–	Sell	-2,100	Closed	-$204K	–	2171
2018 Q3	$204K	Sell	2,100 -1,800	-46%	-$180K	﹤0.01%	2122
2018 Q2	$367K	Sell	3,900 -5,600	-59%	-$490K	﹤0.01%	1938
2018 Q1	$770K	Buy	9,500 +5,000	+111%	+$429K	﹤0.01%	1413
2017 Q4	$401K	Buy	+4,500	New	+$391K	0.01%	824

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Securities's BMRN Position: Q2 2026 in Review

Two Sigma Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 22,096 shares — an estimated $1.25M sold.

Two Sigma Securities first reported a position in BMRN in Q2 2017 and held it in 18 quarters. The position peaked at $7.27M in Q3 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Two Sigma Securities reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 22,096 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
Two Sigma Securities first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 18 quarters.
Two Sigma Securities's BioMarin Pharmaceuticals position peaked at $7.27M in Q3 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.